Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters
Guardado en:
| Publicado en: | BMC Research Notes vol. 12 (2019), p. n/a |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , , , |
| Publicado: |
Springer Nature B.V.
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 2306813775 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1756-0500 | ||
| 024 | 7 | |a 10.1186/s13104-019-4653-x |2 doi | |
| 035 | |a 2306813775 | ||
| 045 | 2 | |b d20190101 |b d20191231 | |
| 084 | |a 113109 |2 nlm | ||
| 100 | 1 | |a Atif Ali Hashmi | |
| 245 | 1 | |a Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters | |
| 260 | |b Springer Nature B.V. |c 2019 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Objectives Ki67 is the most commonly used marker to evaluate proliferative index in breast cancer, however no cutoff values have been clearly defined for high ki67 index. Cancer management should be according to loco-regional profile; therefore, we aimed to determine ki67 index in 1951 cases of intrinsic breast cancer subtypes and its association with other prognostic parameters in our set up. Results Triple negative breast cancers showed highest ki67 index (mean 50.9 ± 23.7%) followed by Her2neu (mean 42.6 ± 21.6%) and luminal B cancers (mean 34.9 ± 20.05%). Metaplastic and medullary breast cancers significantly showed higher ki67 index as compared to ductal carcinoma, NOS. No significant association of ki67 index was noted with any of the histologic parameters in different subtypes of breast cancer expect for tumor grade. Although, ki67 index is a valuable biomarker in breast cancer, however no independent prognostic significance of ki67 could be established in our study. | |
| 651 | 4 | |a Pakistan | |
| 651 | 4 | |a Karachi Pakistan | |
| 653 | |a Biomarkers | ||
| 653 | |a Breast cancer | ||
| 653 | |a Flow cytometry | ||
| 653 | |a Gene amplification | ||
| 653 | |a Studies | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Chemotherapy | ||
| 653 | |a Biopsy | ||
| 700 | 1 | |a Kashif Ali Hashmi | |
| 700 | 1 | |a Muhammad Irfan | |
| 700 | 1 | |a Saadia Mehmood Khan | |
| 700 | 1 | |a Edhi, Muhammad Muzzammil | |
| 700 | 1 | |a Javaria Parwez Ali | |
| 700 | 1 | |a Shumaila Kanwal Hashmi | |
| 700 | 1 | |a Huda Asif | |
| 700 | 1 | |a Faridi, Naveen | |
| 700 | 1 | |a Khan, Amir | |
| 773 | 0 | |t BMC Research Notes |g vol. 12 (2019), p. n/a | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/2306813775/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/2306813775/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/2306813775/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |